Legal
Dokima Trial Terms
Last updated: 3 August 2026
These terms govern an approved evaluation of Dokima by the business identified in a trial application (“Evaluator”). They are between Evaluator and Northloom Ltd, a company registered in Scotland under company number SC895860 with registered office at 5 South Charlotte Street, Edinburgh, EH2 4AN (“Northloom”).
1. Acceptance and business use
By accepting a trial licence, installing or using Dokima, Evaluator agrees to these terms and the Acceptable Use Policy. The person accepting confirms that they can bind Evaluator. Dokima trials are business-to-business only and are not offered to consumers.
2. Approval and eligibility
Trials require Northloom’s prior approval and customer, destination, end-use and sanctions screening. Northloom may approve or decline an application in its discretion and may request supporting information.
Evaluator must be established in the United States, Canada, United Kingdom, Australia, New Zealand, Jersey, Guernsey or Isle of Man. Dokima may be procured, installed and ordinarily used only for Evaluator operations in those places and by users ordinarily based there.
A user may continue using an existing authorised installation during temporary and incidental travel elsewhere, but must not procure, install or deploy Dokima for an operation or establishment outside those places, make it available to a person ordinarily based elsewhere, or use it contrary to export, sanctions or other applicable law.
3. Trial licence and period
Subject to these terms, Northloom grants Evaluator a limited, non-exclusive, non-transferable, non-sublicensable, revocable licence to install and use Dokima solely for internal evaluation.
The trial lasts 21 days beginning on first activation, unless Northloom states another period in writing. A trial may be limited by organisation, user, contributor, repository, version or other reasonable technical controls. Only one trial is permitted per organisation unless Northloom agrees otherwise.
The trial is for evaluation, not for resale, provision of services to third parties, or use as Evaluator’s sole or continuing production security control. Evaluator may review its real repositories to assess suitability, but remains responsible for normal security controls and all decisions based on trial output.
4. Restrictions and responsibilities
Evaluator must:
- own, control or have clear permission to assess every repository and item of source code reviewed;
- comply with the Acceptable Use Policy and applicable law;
- protect licence material, credentials, repositories and results;
- use suitably qualified human review to verify findings before acting or disclosing them; and
- stop using and delete Dokima and trial licence material when the trial ends.
Evaluator must not sell, rent, sublicense, distribute, publish, host for third parties, bypass trial controls, remove proprietary notices or reverse engineer Dokima except where law does not permit that restriction.
5. AI runners and data
Dokima orchestrates AI runners chosen and configured by Evaluator. Evaluator supplies and pays for its runner and is responsible for the runner provider’s terms, security, data retention, training practices, international transfers, usage limits and output.
Dokima runs locally. Repositories, prompts, findings, reports and local state remain in Evaluator’s environment by default, except where Evaluator intentionally sends them to its runner, Northloom support or a separately documented service. Evaluator should not send Northloom personal data, secrets or repository content unless reasonably necessary and lawfully disclosed.
Northloom’s Privacy Notice explains its processing of trial applications, business contacts, screening and support data.
6. Ownership and feedback
Northloom and its licensors own Dokima, its Documentation and underlying technology. Evaluator retains its rights in its repositories and other materials, and in reports produced from them, subject to Northloom’s rights in the product and report templates.
Feedback is voluntary. If provided, Evaluator permits Northloom to use it without charge, provided Northloom does not identify Evaluator or disclose its confidential information.
7. Support, availability and changes
The trial is provided without a service level or guaranteed support or response time. Northloom may change, limit, suspend or discontinue the trial, or revoke trial access, at any time. Where practical, Northloom will give notice.
Neither a trial nor discussions about it obliges either party to enter a paid agreement. Continued use after the trial requires an accepted Order under the Subscription and Software Licence Terms.
8. Confidentiality
Each party will protect the other’s non-public technical, business and commercial information with reasonable care, use it only for the trial and disclose it only to people who need it and are subject to confidentiality duties. The usual exceptions apply to information lawfully known, independently developed, received without restriction or made public without breach. Disclosure required by law is permitted, with prior notice where legally allowed.
9. Compliance and termination
Evaluator must comply with applicable export-control, sanctions, trade and anti-bribery law. Evaluator represents that neither it nor, to its knowledge after reasonable checks, its controlling owners or intended end users is a prohibited or sanctioned person, and that Dokima will not be used for a prohibited end use or diverted to a prohibited destination.
Northloom may immediately suspend or terminate the trial for suspected misuse, inaccurate application information, legal or sanctions risk, security risk or breach. On expiry or termination, the trial licence ends. Local findings and reports are not erased by Northloom, but no new reviews may be run under the expired trial.
10. No warranty
Dokima and all trial support are provided “as is” and “as available” for evaluation. To the fullest extent permitted by law, Northloom excludes all warranties, conditions and terms not expressly stated. Northloom does not warrant uninterrupted or error-free operation, compatibility with every repository or runner, discovery of every vulnerability, absence of false positives or negatives, or any security or compliance outcome.
Dokima is not a replacement for professional judgement, secure development, testing, penetration testing, legal advice or an independent security assessment.
11. Liability
Nothing excludes or limits liability that cannot lawfully be excluded or limited, including liability for death or personal injury caused by negligence, fraud or fraudulent misrepresentation.
Subject to that sentence, Northloom is not liable for loss of profit, revenue, business, savings, goodwill, opportunity or contracts; loss or corruption of data; business interruption; or indirect or consequential loss arising from the trial.
Subject to the first paragraph of this section, Northloom’s total aggregate liability arising from the trial, whether in contract, delict (including negligence), breach of statutory duty or otherwise, is limited to £100. Evaluator is responsible for backups, security controls and human validation of output.
12. General
These terms, the Acceptable Use Policy and any written trial approval are the entire agreement for the trial. Evaluator may not assign them without Northloom’s written consent. A delay in enforcing a right is not a waiver. If a provision is unenforceable, it will be adjusted to the minimum extent necessary and the remainder will continue. A person who is not a party has no right to enforce these terms.
Notices to Northloom should be sent to contact@northloom.ai. Support requests may be sent to support@dokima.net.
13. Governing law and courts
These terms and any non-contractual obligations or disputes arising from them are governed by the laws of Scotland. The courts of Scotland have exclusive jurisdiction.